Jubilant Life Sciences’ subsidiary -- Cadista Holdings Inc -- has filed a Registration Statement on Form 10, General Form for Registration of Securities with the Securities and Exchange Commission (SEC), USA, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This registration is mandatory, as the number of shareholders of the company has increased beyond 500 as of March 31, 2011. The registration does not constitute an offering of securities by Cadista and no fresh money is being raised by Cadista.
Jubilant, through its subsidiaries, owns 82.4% of common stock of Cadista. Cadista through its operating subsidiary Jubilant Cadista Pharmaceuticals Inc, is engaged in the development, manufacture, sale and distribution of prescription generic pharmaceutical products in the United States from its USFDA approved manufacturing facility located at Salisbury in Maryland.
Post filing, the SEC will review the Form 10 Registration Statement and provide its comments. The Form 10 Registration Statement will need revision until deemed accepted and declared effective by the SEC.
Subsequent to the Form 10 Registration Statement being declared effective, Cadista will be a reporting company under the Exchange Act and will be subject to its periodic filing requirements, including the filing of Annual Reports on Form 10?K, Quarterly Reports on Form 10?Q and Current Reports on Form 8?K and will be required to comply with all other obligations of the Exchange Act. While, it is expected that Cadista shares will commence trading on the OTC Bulletin Board, there can be no assurance that this will be the case or that market makers will make a market in the stock.
Jubilant Life Sciences is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider out of India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
